ESMO Breast Cancer 2024
ESMO Breast Cancer 2024
Advertisement
Rob DillardESMO Breast Cancer 2024 | May 16, 2024
The HER2DX ERBB2 mRNA score was significantly associated with improved survival in patients with metastatic HER2+ BC.
Read More
Rob DillardESMO Breast Cancer 2024 | May 16, 2024
Breast cancer survivors with metabolic syndrome have shorter disease-free survival than those without metabolic syndrome.
Rob DillardESMO Breast Cancer 2024 | May 15, 2024
Breast cancer survivors have a modestly increased risk of type 2 diabetes, largely driven by breast cancer treatment.
Rob DillardESMO Breast Cancer 2024 | May 15, 2024
Using the HER2DX genomic tool is feasible in a real-world setting of patients with early-stage HER2-positive breast cancer.
Rob DillardESMO Breast Cancer 2024 | May 15, 2024
Patients with breast cancer who have high levels of glycosylated hemoglobin have an increased risk of recurrence and death.
Rob DillardESMO Breast Cancer 2024 | May 15, 2024
Breast cancer patients have an increased risk of cardiovascular disease compared with the general female population.
Advertisement
Advertisement
Advertisement
Latest News

June 19, 2024